

Product Pipeline

| | Phase I | Phase II | Phase III | Registration | Approval |
|------------------------------------------------------------------------|---------|----------|---------------------------------------------------|--------------|----------|
| <u>Neratinib: Tyrosine kinase inhibitor</u> | | | | | |
| HER2+ Breast Cancer | | | | | |
| Extended adjuvant <i>Neratinib monotherapy</i> | | | ExteNET (Phase III HER2+ EBC*) | | |
| Metastatic <i>Monotherapy or combo therapy</i> | | | NALA (Phase III 3 rd Line HER2+ MBC**) | | |
| Metastatic w/ brain mets <i>Monotherapy or combo therapy</i> | | | TBCRC-022 (T-DM1 + neratinib) | | |
| HER2-mutant Solid Tumors | | | SUMMIT | | |
| <u>Alisertib: Aurora kinase A inhibitor</u> | | | | | |
| HRc+ HER2-negative MBC | | | TBCRC-041 (fulvestrant + alisertib) | | |
| Triple-negative MBC | | | NCT02187991 (paclitaxel + alisertib) | | |
| Small cell lung cancer | | | NCT02038647 (paclitaxel + alisertib) | | |

*